Progenity Buys Carmenta Bioscience

San Diego-based Progenity, which provides complex molecular and specialized diagnostic testing services, announced this morning that it has acquired Carmenta Bioscience, a developer of diagnostics for preeclampsia. Financial terms of the deal were not announced by the companies. Progenity said that Carmenta's CEO, Matthew Cooper, Ph.D., has been named as its Chief Scientific Officer.